Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Metabolic reprogramming is a hallmark of cancer.
• Sterol regulatory element binding protein-2 (SREBP-2) regulates cholesterol biosynthesis and homeostasis.
• SREBP-2 controls the mevalonate pathway, crucial for cell proliferation.

Purpose of the Study:

• To review the role of SREBP-2 and the mevalonate pathway in cancer progression.
• To explore SREBP-2 and its targets as potential therapeutic strategies in oncology.
• To summarize current preclinical and clinical findings on drugs targeting this pathway.

Main Methods:

• Literature review of SREBP-2 structure, activation, and regulation.
• Analysis of SREBP-2 and mevalonate pathway enzyme involvement in various cancers.
• Summary of therapeutic agents targeting SREBP-2 and related enzymes.

Main Results:

• SREBP-2 and mevalonate pathway enzymes (HMGCR, FPPS, SQS, DHCR4) are implicated in prostate, breast, lung, and hepatocellular cancers.
• Fatostatin, statins, and N-BPs target SREBP-2, HMGCR, and FPPS, respectively.
• These agents show promise in preclinical and clinical cancer treatment, alone or in combination.

Conclusions:

• The SREBP-2-regulated mevalonate pathway is a critical player in cancer development.
• Targeting this pathway represents a viable and emerging therapeutic approach for diverse cancers.
• Further research into SREBP-2 inhibitors could lead to novel cancer treatments.